Logotype for Acumen Pharmaceuticals Inc

Acumen Pharmaceuticals (ABOS) investor relations material

Acumen Pharmaceuticals Cantor Global Healthcare Conference 2025 summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Acumen Pharmaceuticals Inc
Cantor Global Healthcare Conference 2025 summary5 Sep, 2025

Company and scientific background

  • Sabirnetug is a humanized monoclonal antibody with high selectivity for toxic amyloid-beta oligomers, originating from academic research and later reacquired from Merck as a wholly owned asset.

  • The oligomer hypothesis posits that soluble amyloid-beta aggregates are the primary neurotoxic species in Alzheimer's, disrupting synaptic function and linking A-beta to tau pathology.

  • Sabirnetug demonstrates 10,000-fold selectivity for oligomers over monomers and 90-fold over plaques, aiming to minimize target distraction and maximize efficacy.

  • Decades of research support the toxicity of oligomers, and sabirnetug targets a broad spectrum of these aggregates, potentially offering a differentiated therapeutic effect.

  • Monoclonal antibody specificity is crucial, and sabirnetug’s mechanism is designed to impact synaptic plasticity and cortical function by targeting oligomers.

Clinical development and trial data

  • Phase 1b INTERCEPT-AD trial in early Alzheimer's patients showed sabirnetug was well tolerated, with a 10% ARIA rate across dose groups, and consistent pharmacokinetics for monthly dosing.

  • PET imaging revealed a 20% reduction in amyloid plaque at the highest dose, and biomarker analysis indicated reversal of disease-related markers, supporting the drug’s mechanism.

  • Target engagement was confirmed using a novel ELISA-based assay, with maximal engagement at 25 and 60 mg/kg doses.

  • Lower ARIA rates compared to other antibodies may be due to IgG2 isotype and higher selectivity for oligomers over plaques.

  • No direct correlation was observed between plaque reduction and ARIA, highlighting the complexity of the underlying biology.

Phase 2 ALTITUDE-AD study and trial design

  • Phase 2 ALTITUDE-AD is an 18-month, well-powered study in early Alzheimer's, using 35 and 50 mg/kg IV doses every four weeks, with IDRS as the primary outcome.

  • Enrollment completed with 532 subjects in 10 months across the US, Canada, Germany, and Spain, reflecting strong interest and efficient execution.

  • The cohort is similar to those in other major trials, and the IDRS scale was strategically chosen for its sensitivity in early AD.

  • Dose modeling supports adequate target coverage at both dose levels, with expectations for differentiated ARIA rates between cohorts.

  • A two-step screening process using plasma pTau217 biomarker improved efficiency, reducing amyloid-negative screen failures and streamlining enrollment.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Acumen Pharmaceuticals earnings date

Logotype for Acumen Pharmaceuticals Inc
Q3 202511 Nov, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Acumen Pharmaceuticals earnings date

Logotype for Acumen Pharmaceuticals Inc
Q3 202511 Nov, 2025

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Acumen Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company primarily engaged in the discovery and development of therapies for the treatment of Alzheimer's disease. The company's most advanced candidate is ACU193, a humanized monoclonal antibody designed to target toxic soluble amyloid-beta oligomers. These amyloid-beta oligomers are associated with the neurodegeneration seen in Alzheimer’s disease patients. Acumen Pharmaceuticals was founded in 1996 and focuses on progressing its immunotherapy approach to offer potential disease-modifying treatments. The company is headquartered in Charlottesville, Virginia, and its shares are listed on the NASDAQ.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage